Revenue: As of FY2027 Q1, the actual value is USD 1.442 M, missing the estimate of USD 2.339 M.

EPS: As of FY2027 Q1, the actual value is USD -0.26, beating the estimate of USD -0.3214.

EBIT: As of FY2027 Q1, the actual value is USD -329.07 M.

Financial Summary for the Three Months Ended June 30, 2026

Revenue

Revenue was $1.442 million for the three months ended June 30, 2026, compared to $2.170 million for the same period in 2025.

Operating Expenses

• Cost of Revenues: Increased to $284 thousand for the three months ended June 30, 2026, from $154 thousand in the prior year period.
• Research and Development (R&D) Expenses: Increased by $49.1 million to $202.0 million for the three months ended June 30, 2026, from $152.9 million for the same period in 2025. This increase was primarily driven by a $49.4 million rise in program-specific costs, including $44.8 million for the anti-FcRn franchise and $4.7 million for mosliciguat, and a $3.8 million increase in personnel-related expenses, including $4.1 million in employee bonuses related to the Moderna settlement. Non-GAAP R&D expenses were $192.9 million for the three months ended June 30, 2026, compared to $141.0 million for the same period in 2025.
• General and Administrative (G&A) Expenses: Increased by $31.5 million to $165.5 million for the three months ended June 30, 2026, from $134.0 million for the same period in 2025. This was mainly due to a $26.1 million increase in personnel-related expense, including $18.8 million in employee bonuses from the Moderna settlement and $6.3 million in employer payroll taxes. Non-GAAP G&A expenses were $90.7 million for the three months ended June 30, 2026, compared to $62.6 million for the same period in 2025.
• Total Operating Expenses: Totaled $367.827 million for the three months ended June 30, 2026, up from $287.092 million in the prior year period.

Net Loss

Net loss was - $290.6 million for the three months ended June 30, 2026, compared to - $273.9 million for the same period in 2025. Net loss attributable to Roivant Sciences Ltd. was - $189.837 million for the three months ended June 30, 2026, compared to - $223.355 million for the same period in 2025. Non-GAAP net loss was - $243.7 million for the three months ended June 30, 2026, compared to - $170.1 million for the same period in 2025.

Cash Position and Marketable Securities

As of June 30, 2026, Roivant Sciences Ltd. had consolidated cash, cash equivalents, restricted cash, and marketable securities of $3.9 billion, which supports a cash runway into profitability, excluding the cash payment received from Moderna in July. Cash and cash equivalents were $1,248,456 thousand as of June 30, 2026, down from $1,419,232 thousand as of March 31, 2026. Marketable securities were $2,593,626 thousand as of June 30, 2026, down from $2,872,601 thousand as of March 31, 2026.

Litigation Settlement and Other Financial Items

Genevant and Arbutus received an initial payment of $950 million from Moderna in July 2026 as part of a $2.25 billion patent infringement settlement, with an additional $1.3 billion contingent on a favorable resolution of Moderna’s § 1498 appeal. Roivant Sciences Ltd. recognized a gain on litigation settlement of $392 thousand for the three months ended June 30, 2026. Change in fair value of investments was - $36,637 thousand for the three months ended June 30, 2026, compared to $19,125 thousand in the prior year period. Interest income was - $36,922 thousand for the three months ended June 30, 2026, compared to - $48,322 thousand in the prior year period.

Share Repurchases

For the three months ended June 30, 2026, Roivant Sciences Ltd. repurchased 7.3 million common shares for approximately $208.7 million.

Balance Sheet Data

As of June 30, 2026, total assets were $5,306,493 thousand, compared to $5,708,687 thousand as of March 31, 2026. Total liabilities were $384,624 thousand as of June 30, 2026, compared to $416,275 thousand as of March 31, 2026. Total shareholders’ equity was $4,921,869 thousand as of June 30, 2026, compared to $5,292,412 thousand as of March 31, 2026.

Outlook / Guidance

Roivant Sciences Ltd. anticipates the commercial launch of brepocitinib in dermatomyositis by the end of September 2026, with key topline data readouts expected in the second half of calendar year 2026 for brepocitinib, IMVT-1402, and mosliciguat in various indications. Further topline data for IMVT-1402 in Graves’ disease and myasthenia gravis are expected in calendar year 2027, and in chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease in calendar year 2028. Additionally, Genevant and Arbutus filed new international lawsuits against Pfizer and BioNTech in 21 jurisdictions in July 2026, seeking to enforce patent rights related to lipid nanoparticle technology.